Management of Thrombotic Microangiopathic Hemolytic Anemias with Therapeutic Plasma Exchange: When It Works and When It Does Not

Hematol Oncol Clin North Am. 2016 Jun;30(3):679-94. doi: 10.1016/j.hoc.2016.01.009. Epub 2016 Mar 30.

Abstract

Thrombotic microangiopathies are a heterogeneous group of inherited and acquired disorders sharing a common clinical presentation of microangiopathic hemolytic anemia, thrombocytopenia, and organ damage. These disorders have been treated with plasma exchange (TPE) based on randomized controlled trials, which found this therapy to be effective in thrombotic thrombocytopenic purpura (TTP). For the remaining disorders, low- to very low-quality evidence exists for the use of TPE. When TPE is applied, the treatment regimen used for TTP is usually applied. There is a need for further evaluation of the role of TPE in the treatment of thrombotic microangiopathies other than TTP.

Keywords: Apheresis; Hemolytic uremic syndrome; Plasma exchange; Plasmapheresis; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura.

Publication types

  • Review

MeSH terms

  • Anemia, Hemolytic / complications
  • Anemia, Hemolytic / therapy*
  • Humans
  • Plasma Exchange / adverse effects
  • Plasma Exchange / methods*
  • Purpura, Thrombotic Thrombocytopenic / complications
  • Purpura, Thrombotic Thrombocytopenic / therapy*
  • Randomized Controlled Trials as Topic